Profound Medical’s TULSA Procedure Outperforms Robotic Surgery in Penile Length Preservation
Event summary
- Profound Medical’s TULSA Procedure showed no median change in penile length at 1 month post-treatment, compared to a 0.65 cm reduction with robotic radical prostatectomy.
- The CAPTAIN trial, which exceeded its enrollment target of 201 patients by treating 211, demonstrated statistically significant superiority of TULSA over robotic RP in preserving erectile function and urinary continence at 6 months.
- Results were presented by Xiaosong Meng, MD, PhD, at the Society of Robotic Surgery Annual Meeting on July 24, 2026.
The big picture
Profound Medical’s CAPTAIN trial results challenge the dominance of robotic radical prostatectomy by highlighting superior quality-of-life outcomes for patients. This positions MRI-guided therapies as a compelling alternative in prostate cancer treatment, particularly as healthcare systems prioritize patient-centered care and cost-effectiveness. The findings could reshape competitive dynamics in urological oncology, where minimally invasive options are increasingly favored.
What we're watching
- Clinical Adoption
- How the CAPTAIN trial results will influence urologists' preference for TULSA over robotic surgery in intermediate-risk prostate cancer cases.
- Regulatory Impact
- Whether these findings accelerate regulatory approvals or reimbursement policies favoring MRI-guided therapies like TULSA.
- Market Expansion
- The pace at which Profound Medical can scale commercialization of the TULSA Procedure in global markets beyond the U.S., Canada, and Europe.